Artivion, Inc. (AORT)

Market Cap	1.14B
Revenue (ttm)	384.90M
Net Income (ttm)	-842,000
Shares Out	41.92M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	68.51
Dividend	n/a
Ex-Dividend Date	n/a

Volume	221,972
Open	26.87
Previous Close	26.93
Day's Range	26.63 - 27.30
52-Week Range	15.80 - 30.00
Beta	1.75
Analysts	Strong Buy
Price Target	31.00 (+14.1%)
Earnings Date	Nov 7, 2024

About AORT

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shel...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 11, 1993
• Employees: 1,500
• Stock Exchange: NYSE
• Ticker Symbol: AORT
• Website: https://artivion.com

Financial Performance

In 2023, Artivion's revenue was $354.00 million, an increase of 12.82% compared to the previous year's $313.79 million. Losses were -$30.57 million, 60.1% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for AORT stock is "Strong Buy." The 12-month stock price forecast is $31.0, which is an increase of 14.10% from the latest price.

Price Target

$31.0

(14.10% upside)

Analyst Consensus: Strong Buy